Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx to $606 from $544 and keeps an Overweight rating on the shares. The firm cites Vyvgart’s pos CIDP data. Wells continues to view Vyvgart as a multi-billion drug that is derisked for many future IgG mediated diseases-says “there is so much more to come.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX: